Source comparison
Visceral fat versus subcutaneous fat
Not all fat is equivalent from a metabolic standpoint, and this distinction matters when comparing sermorelin and GLP-1 therapy. Visceral fat, the fat packed around internal organs deep in the abdomen, is far more metabolically damaging than subcutaneous fat,
This comparison does not assign a generated winner or score.
- Not all fat is equivalent from a metabolic standpoint, and this distinction matters when comparing sermorelin and GLP-1 therapy. Visceral fat, the fat packed around internal organs deep in the abdomen, is far more metabolically damaging than subcutaneous fat, which sits just beneath the skin. Visceral fat secretes inflammatory cytokines, impairs insulin sensitivity, and contributes directly to cardiovascular disease risk. Reducing visceral fat is more clinically meaningful than reducing subcutaneous fat, even if the scale weight change looks similar.
- Both GLP-1 medications and sermorelin reduce visceral fat, but through different mechanisms. GLP-1 medications reduce overall caloric intake, producing a generalized fat reduction that includes visceral deposits. The visceral fat loss on semaglutide and tirzepatide is often preferential in the early stages, partly because visceral fat is more metabolically accessible than deep subcutaneous stores. Sermorelin, through GH and IGF-1 elevation, specifically targets visceral adiposity. GH deficiency is characterized by pathologically elevated visceral fat accumulation, and GH restoration through GHRH analogs consistently reduces visceral fat in deficient patients, even without dramatic scale weight changes.
- This is why body composition measurements, specifically DEXA scans or body fat percentage measurements, are more informative than scale weight for evaluating sermorelin protocols. A person on sermorelin who loses three pounds of visceral fat while gaining two pounds of muscle has genuinely improved their metabolic health, even though the scale shows only a one-pound difference. For those tracking changes across a GLP-1 protocol, understanding the distinction between fat types also helps interpret tirzepatide before and after results and tirzepatide weight loss results over time.